StockNews将FibroGen(FGEN)作为“控股”,而其首席执行官和其他内幕人士则购买FibroBiologics(FBLG)的股份。 StockNews rates FibroGen (FGEN) a "hold", while its CEO and other insiders buy shares of FibroBiologics (FBLG).
股票新闻报道了FibroGen (纳斯达克:FGEN),给它一个"持有"评级. StockNews covers FibroGen (NASDAQ: FGEN), giving it a "hold" rating. FGEN的股票以0.39美元开放,市场上限为38.30亿美元。 FGEN's stock opened at $0.39 with a market cap of $38.30M. 公司报告Q的每股收益为0.16美元,超过估计的0.09美元. The company reported EPS of ($0.16) for Q, beating estimates by $0.09. 其产品包括第三阶段癌症和贫血治疗。 Its products include Phase III cancer and anemia treatments. StockNews还报道了FibroBiologics（纳斯达克股票代码：FBLG）的内部购买，包括首席执行官Pete O'Heeron和Hamid Khoja，他们都在8月12日购买了股票。 StockNews also reports insider purchases for FibroBiologics (NASDAQ: FBLG), including CEO Pete O'Heeron and Hamid Khoja, both buying shares on August 12th.